Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment

International Journal of Hematology

Volumn 86, Issue 1, 2007, Pages 66-68

  Bruck P ^a   Mousset, S ^a   Bohme A ^a   Hoelzer, D ^a   Atta, J ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Primary plasma cell leukemia; Thalidomide

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

AGED; ANEMIA; ARTICLE; BLOOD SMEAR; BONE MARROW BIOPSY; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG MEGADOSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA RELAPSE; LEUKOCYTE; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PLASMA CELL LEUKEMIA; POOR GENERAL CONDITION; RARE DISEASE; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FATAL OUTCOME; HUMANS; LEUKEMIA, PLASMA CELL; MALE; NEOPLASM RECURRENCE, LOCAL; THALIDOMIDE;

EID: 34547634416     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0617     Document Type: Article

References (15)

1. Kosmo MA, Gale RP. Plasma cell leukemia. Semin Hematol. 1987;24:202-208.
2. Bladé J, Kyle RA. Non-secretory myeloma, immunglobulin D myeloma and plasma cell leukemia. Hematol Oncol Clin North Am. 2000;13:1259-1272.
3. García-Sanz R, Orfào A, González M, et al. Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy and cytogenetic characteristics. Blood. 1999;93:1032-1037.
4. Kawada E, Shinonone S, Saitoh T, et al. Primary non-secretory plasma cell leukemia: a rare variant of multiple myeloma. Ann Hematol. 1999;78:25-27.
5. Pellat-Deceunynck C, Barillé S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12):1977-1982.
6. Costello R, Sainty D, Bouabdallah R, et al. Primary plasma cell leukemia: a report of 18 cases. Leuk Res. 2001;25:103-107.
7. Robak T, Urbanska-Rys H, Robak E, et al. Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features. Leuk Lymphoma. 2002;43:1067-1073.
8. Christou L, Hatzimichael E, Chaidos A, Tsiara S, Bourantes KL. Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone. Eur J Haematol. 2001;67:51-53.
9. Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol. 2002;81:362-367.
10. Yamagata N, Shimazaki C, Goto H, et al. IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon alpha. Am J Hematol. 1994;45:262-264.
11. Hovenga S, de Wolf JT, Klip H, Vellanga E. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant. 1997;20:901-904.
12. Cernelc P, Mlakar U. Maintenance treatment of primary plasma cell leukemia with interferon alpha. Transplant Proc. 2002; 34:2929-2930.
13. Gemmel C, Cremer FW, Weis M, et al. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol. 2002;81:119-123.
14. Hideshima T, Chauhan D, Podar K, et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment Semin Oncol. 2001;28:607-612.
15. Johnston RE and Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymph. 2002;43:351-354.